Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is a research organization focusing on therapies for patients which include drugs that are in development. With corporate headquarters in Nashville, Tennessee, United States, it conducts community-based clinical trials in oncology, cardiology, gastroenterology, and other therapeutic areas.[1] The current CEO is Dee Anna Smith.[2][3]

Sarah Cannon Research Institute
TypeSubsidiary
IndustryHealth care
Headquarters
Nashville
,
United States
Area served
United States, United Kingdom
ParentHospital Corporation of America
Websitehttps://sarahcannon.com/

SCRI accrued more than 2,500 patients to cancer trials in 2009, including more than 500 to Phase I investigational studies.[4] Non-oncology trials accounted for nearly 1,500 additional patients for a total of almost 4,000.[5]

Its drug development program has conducted 400+ "first-in-human" trials.[6] SCRI has been involved in the testing and development of about 10 drugs that have been approved since 1999.[7]

SCRI employs over 350 people[7] and was No. 4 on NashvillePost magazine's 2010 list of the Best Employers in Middle Tennessee.[8] In 2009[9] and 2010, SCRI was awarded a spot on Modern Healthcare's list of the 100 Best Places to Work in Healthcare.[10]

History

SCRI was formed in 2004 through a joint venture between Tennessee Oncology and HCA. Before helping form SCRI, Tennessee Oncology had conducted research on behalf of the Minnie Pearl Research Network since 1993.[11]

SCRI started a cardiovascular initiative in 2008.[7] Currently, there are three strategic sites for cardiovascular research: Redmond Regional Medical Center in Rome, Georgia, Centennial Heart in Nashville, Tennessee, and Osceola Regional Medical Center in Kissimmee, Florida.

The Global Services division was created in 2010 to provide project management, clinical monitoring, data management, biostatistics, safety, medical writing, quality assurance and data safety monitoring boards on a global platform.[12]

Headquarters

SCRI's headquarters are in Nashville, Tennessee, United States. Its multi-specialty division is based in Memphis, Tennessee. Sarah Cannon Research UK is headquartered in London, England.

Other locations

SCRI works with 57 sites in 24 states and the United Kingdom. This includes six oncology strategic sites and 11 multi-specialty strategic sites.

Oncology strategic sites include:

Multi-specialty strategic sites include:

References
  1. "About Sarah Cannon Cancer Care and Research". Sarah Cannon.
  2. www.bizjournals.com https://www.bizjournals.com/nashville/news/2019/02/28/the-boss-you-can-t-scare-dee-anna-smith-she-s-used.html. Retrieved 2020-05-08. Missing or empty |title= (help)
  3. "Sarah Cannon CEO Dee Anna Smith discusses distinctiveness, leadership at Heroes of Business chapel". Lumination Network. 2013-11-01. Retrieved 2020-05-08.
  6. "Site Management Organization". Sarah Cannon. Retrieved 2020-01-14.
  9. "Modern Healthcare's Best Places to Work in Healthcare - 2009 (Alphabetical List)". Modern Healthcare. 3 September 2009.
  10. "Modern Healthcare's 2010 Best Places to Work in Healthcare (Alphabetical List)". Modern Healthcare. 3 September 2010.
  12. "SCRI adds division leadership". Nashville Post.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.